Librela (bedinvetmab) is a monthly injection approved to control pain associated with osteoarthritis in dogs. NSAIDs, such as carprofen and meloxicam, are also commonly prescribed for arthritis pain.

But approval of each medication does not establish that using them together is safe. For anyone considering this combination, the U.S. prescribing information contains an important precaution.

What the package insert actually says

The official U.S. Librela package insert states:

“The safe use of anti-NGF monoclonal antibodies with concurrent non-steroidal anti-inflammatory drugs (NSAIDs) has not been established in dogs.”

The insert also describes a human safety concern: rapidly progressing osteoarthritis occurred in some patients receiving anti-nerve growth factor therapy, with a higher incidence among those also taking NSAIDs long term.

Human findings do not prove that the same outcome will occur in dogs. However, their inclusion in the veterinary label makes them relevant to treatment decisions.

The insert also describes a small study involving eight dogs given Librela alongside 14 days of an injectable NSAID. It specifically concludes that this study did not provide enough data to establish the safety of concurrent treatment.

That means a short course of overlap cannot accurately be described as “proven safe” based on this study.

What the FDA’s veterinarian letter adds

The FDA’s Dear Veterinarian letter about Librela discusses reported adverse events, including balance problems, seizures, weakness or inability to rise, urinary incontinence, and increased drinking and urination. Some reports included death or euthanasia.

The letter encourages veterinarians to report suspected adverse events and provide a complete medical history.

It does not specifically prohibit combining Librela with an NSAID. It also does not establish that NSAID coadministration caused the reported events. These distinctions matter when explaining the FDA’s position.

What about the manufacturer’s website?

The official U.S. Librela veterinarian website describes the product’s benefits and safety information, links to the prescribing information, and directs veterinarians to rely on product labels when making clinical decisions.

General statements about Librela’s safety do not resolve the specific uncertainty about concurrent NSAID treatment. The combination precaution remains relevant even when the individual drugs are commonly used.

What does this mean for a veterinarian who prescribes both?

My clinical interpretation is that knowingly prescribing both medications requires a deliberate, patient-specific decision.

The veterinarian should be able to explain why the combination is being chosen, what alternatives were considered, and why the expected benefit justifies proceeding despite the uncertainty. The owner should understand that combination safety has not been established and that the label identifies a relevant human joint-safety concern.

I would also expect a documented plan for monitoring, reassessment, and responding to deterioration.

These are recommendations for responsible clinical decision-making. They are not a claim that the FDA has issued a specific consent form or documentation checklist for this combination.

There is, however, an explicit owner-communication instruction: the updated labeling directs veterinarians to provide the Client Information Sheet and discuss potential adverse events before each Librela injection. The FDA’s safety-related labeling update explains this requirement and the added safety information.

Does concurrent prescribing automatically mean malpractice?

The FDA documents do not support that blanket conclusion.

Concurrent NSAID use is addressed as a precaution, rather than an express contraindication. Whether an individual prescribing decision constitutes negligence depends on the clinical circumstances, applicable professional standards, and evidence concerning harm and causation.

Still, the precaution deserves meaningful attention. An owner should not be told that the combination is established as safe when the prescribing information says otherwise. Consent also does not replace sound clinical judgment.

For dog owners, a useful question is: “Given that the label says combination safety has not been established, why are both medications appropriate for my dog, and what is our monitoring plan?”

For veterinarians, the responsibility is to give a clear, evidence-based answer—and document the reasoning behind the decision.

If your dog is receiving both medications, contact the prescribing veterinarian to review the plan before making changes. Promptly report new weakness, trouble walking, seizures, changes in urination, or other concerning signs.

References

  1. Librela: Official U.S. prescribing information and Client Information Sheet
  2. FDA: Dear Veterinarian letter concerning adverse events reported in dogs treated with Librela
  3. FDA: Animal Drug Safety-Related Labeling Changes—Librela, February 18, 2025
  4. Zoetis: Official U.S. Librela veterinarian website

Podcast also available on PocketCasts, SoundCloud, Spotify, Google Podcasts, Apple Podcasts, and RSS.

Leave a Reply